Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.

Okay! So my question is would Leronlimab limit the side effects or buy time for CAR T-cells when infused back into the patient to target and destroy myeloma cells. Which therapies do we think we can help?